Erin Leonard
Family Medicine · Mount Ayr, IANPI 1548789043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$480
- AstraZeneca$471
- Lilly USA, LLC$168
- Amgen$146
- E.r. Squibb & Sons, L.L.C.$128
- Novo Nordisk$126
- plus $887 from 23 others
What the payments were for
- Food & beverage$2,35998%
- Education$462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $480 |
| AstraZeneca | 17 | $471 |
| Lilly USA, LLC | 10 | $168 |
| Amgen | 11 | $146 |
| E.r. Squibb & Sons, L.L.C. | 9 | $128 |
| Novo Nordisk | 6 | $126 |
| Boehringer Ingelheim | 6 | $97 |
| AbbVie | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Novartis | 3 | $61 |
| GSK | 4 | $56 |
| Mylan Specialty L.p. | 4 | $55 |
| Insulet Corporation | 1 | $45 |
| Amarin Pharma, Inc. | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Abbott | 1 | $40 |
| Verona Pharma, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Merck | 2 | $32 |
| Johnson & Johnson | 2 | $25 |
| Abiomed | 1 | $20 |
| Zimmer Biomet | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Sobi, Inc | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$2,406 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $33,108 |
| MounjaroTirzepatide | 27 | $27,598 |
| JardianceEmpagliflozin | 18 | $16,593 |
| OzempicSemaglutide | 14 | $14,850 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,081 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $3,717 |
| Febuxostat | 12 | $2,169 |
| Potassium Chloride | 121 | $1,927 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,471 |
| Tretinoin | 13 | $1,405 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,254 |
| Duloxetine Hcl | 46 | $1,008 |
| Temazepam | 18 | $889 |
| Omeprazole | 103 | $888 |
| Levothyroxine Sodium | 151 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $56 | $41,18961 claims |
| Lilly USA, LLCMounjaro | $168 | $27,59827 claims |
| Boehringer IngelheimJardiance | $97 | $16,59318 claims |
| Novo NordiskOzempic | $126 | $14,85014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Mount Ayr
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.